Insights on the Insulin Global Market to 2027 – Featuring AstraZeneca, Biocon, Johnson & Johnson and Merck Among Others –

Insights on the Insulin Global Market to 2027 – Featuring AstraZeneca, Biocon, Johnson & Johnson and Merck Among Others –

Insights on the Insulin Global Market to 2027 – Featuring AstraZeneca, Biocon, Johnson & Johnson and Merck Among Others –

DUBLIN–(BUSINESS WIRE)–The “Insulin Market Research Report by Drug, Application, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to’s offering.

The Global Insulin Market size was estimated at USD 36.16 billion in 2021, USD 40.82 billion in 2022, and is projected to grow at a CAGR of 13.08% to reach USD 75.62 billion by 2027.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Insulin Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Insulin Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Insulin Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Insulin Market?

4. What is the competitive strategic window for opportunities in the Global Insulin Market?

5. What are the technology trends and regulatory frameworks in the Global Insulin Market?

6. What is the market share of the leading vendors in the Global Insulin Market?

7. What modes and strategic moves are considered suitable for entering the Global Insulin Market?

Market Dynamics


  • Growing prevalence of diabetes among the population
  • Increasing incidence of geriatric and obese population
  • Rapid development in insulin delivery systems, drug, and analog development


  • High cost associated with insulin drugs


  • New regulations for insulin biosimilars and rising investments in R&D
  • High potential of insulin drug in emerging economies


  • Strict regulatory norms for the approval of product

Companies Mentioned

  • Adocia
  • AstraZeneca PLC
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Biocon Limited
  • Biodel Inc.
  • Bioton SA
  • Dongbao Enterprise Group Co., Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Julphar
  • MannKind Corporation
  • Medtronic PLC
  • Merck & Co.
  • Novartis International AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals
  • Pfizer Inc.
  • Piramal Healthcare
  • Sanofi SA
  • Teijin Limited
  • Tonghua Dongbao Pharmaceutical Co., Ltd
  • US Vitamins Limited
  • Wockhardt Ltd
  • Ypsomed AG

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900